The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011.
This commentary is written in response to a recent Cochrane Collaboration review published in March 2011 (1). The authors of this commentary would like to express their concerns over the conclusions of the Cochrane review, which state, "There is no firm evidence to support or refute transarterial chemoembolization (TACE) or transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)."
University of Colorado, Department of Radiology, Aurora, CO 80045, USA. Charles.ray@ucdenver.edu
Charles E
CE
Ray
Ziv J
ZJ
Haskal
Jean-Francois H
JF
Geschwind
Brian S
BS
Funaki
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D019317:Evidence-Based Medicine; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents